Andrew Sanchez M.D.
Andrew Sanchez M.D.

@ASanchez_PS

15 Tweets 4 reads Apr 06, 2023
🫀 Approach to HFpEF Dx 🫀
I loved creating this one-pager because my understanding of how to clinch this Dx shifted enormously throughout my intern year.
Turns out, "no diastolic dysfunction" on TTE doesn't = no HFpEF.
Let's go through the pathophys & see how this assists Dx.
The pathophys of HFpEF first involves diastolic dysfunction.
(This may or may not be visualized on TTE; more on this in a second.)
With an expected ↑ LV-EDP during exercise (+/- at rest), LA pressure then ↑.
This will, chronically, lead to LA enlargement.
Pulmonary venous pressure then ↑. In order for forward blood flow to be maintained in the face of this increased pressure, what can be called the "biventricular reflex" ensues, leading to PA vasoconstriction.
Of note, this process (initially) *prevents* pulmonary edema.
However, resultant ↑ RV-EDP, RA-P, & CVP (true "back pressure") *does* lead to peripheral edema 💧🦿
Why is this pathophys important? It means patients w/ peripheral edema & without obvious intra-thoracic fluid do *not* necessarily have isolated R.-heart failure! ❌
When LV-EDP is >18, pulmonary capillary fluid leaks into the interstitium → interstitial edema. In mid-stage HFpEF, this fluid drains into lymphatics ✔️
In late-stages, very high RV-EDP & CVP eliminates the hydrostatic gradient favoring lymph drainage → pleural effusions 😔
Alright, that was a lot of abbreviations & letters.
This should be manageable when viewing the pathophys as a simple sequence of events:
As promised, let's go through my birds'-eye view approach to how to clinch this Dx 🔍
You see a patient with CHF (ie ↑ JVP, edema, exertional dyspnea) & see a TTE with EF >50%...
Step 1: is there physiologic proof of ↑ LV-EDP on imaging?
- Left atrial enlargement?
- Bilateral pleural effusions?
- LVH?
Yes = Dx confirmed! ✅
These findings are *proof*: remember the pathophys!
That's it. It's that simple!
The real key is to not be fooled by the following 🔑 :
- "No diastolic dysfunction" on TTE (absent in ~30%)
- "No LVH" on TTE (absent in ~45%)
If you see b/l pleural effusions (even if *small*), you're *very* likely dealing with HFpEF.
For an objective risk stratification tool, see the H2FPEF score, which may be used to guide the pursuit of exercise right heart catheterization. (Here my expertise departs...)
Finally, don't forget your patient with HFpEF needs an Endpoint Dx: could they have amyloidosis (increasingly recognized), or do they simply have multiple metabolic risk factors?
Framework below adapted from @AndreMansoor.
Reference: amazon.com
🏁 That completes my overview of an approach to HFpEF Dx!
I hope this is viewed as a helpful framework for medicine residents & internists. More nuanced takes definitely available in the @CardioNerds world 🌎
📚Save these notes to Glass here: glass.health
@GlassHealthHQ

Loading suggestions...